What is Centile Bio?
Centile Bio operates at the intersection of artificial intelligence and clinical neuroscience, providing a sophisticated platform that transforms standard MRI and CT imaging into actionable quantitative brain biomarkers. By leveraging machine learning and high-fidelity computational modeling, the company addresses a critical gap in diagnostic precision and longitudinal research. Its technology is engineered to streamline clinical trials and enhance diagnostic accuracy, positioning the firm as a pivotal infrastructure provider for pharmaceutical companies and academic institutions alike. The platform's ability to generate standardized reference models from complex imaging data represents a significant leap forward in neuro-diagnostic capabilities.
How much funding has Centile Bio raised?
Centile Bio has raised a total of $3.1M across 1 funding round:
Private Equity
$3.1M
Private Equity (2026): $3.1M, investors not publicly disclosed
Key Investors in Centile Bio
Undisclosed Investor
An institutional capital partner specializing in late-stage growth equity and enterprise-level technology scaling.
What's next for Centile Bio?
With this major strategic investment, Centile Bio is well-positioned to accelerate its commercial expansion and deepen its integration within the global healthcare ecosystem. The company is expected to prioritize the scaling of its AI-powered analytics suite, focusing on broader regulatory approvals and the expansion of its clinical trial support services. By leveraging this capital, Centile Bio aims to solidify its market leadership, potentially pursuing strategic partnerships with major medical imaging hardware manufacturers to embed its analytics directly into the diagnostic workflow. The focus remains on driving operational efficiency and expanding the utility of its biomarker platform to meet the increasing demand for objective, data-driven neurological assessments.
See full Centile Bio company page
